

SARC Biannual Meeting

November 5, 2009

8:00 am - 12:00 pm

AGENDA

8:00 – 8:15	Welcome/SARC Update	Laurence Baker <i>Chair, SARC Board of Directors</i>
8:15 – 9:20	Chawla/Rosenfeld Developmental Therapeutics Symposium PET Evaluation of Sarcoma Treatment Response: “PERCIST” Criteria Assessing Response in Sarcomas: Methods Are Clear; Results Are Murky	Richard Wahl Scott Schuetze
9:20-9:35	Brief Update: Selected Ongoing and Recently Completed SARC Trials <ul style="list-style-type: none">• SARC 003 Phase 2 Gemcitabine/Docetaxel in Bone Sarcoma• SARC 004 Phase 2 Neoadjuvant Imatinib in DFSP• SARC 005 Phase 2 Adjuvant Therapy High Risk Uterine Leiomyosarcoma• SARC 007 Phase 2 Perifosine in chemoinensitive sarcoma• SARC 009 Phase 2 Dasatinib in metastatic sarcoma	Laurence Baker
9:35-9:50	Break	
9:50-10:10	New directions in therapy for MPNST <ul style="list-style-type: none">• SARC 006 Phase 2 Sporadic vs. NF-associated MPNST• SARC 016 Phase 2 RAD001 with and without bevacizumab in metastatic MPNST	Brigitte Widemann
10:10-10:30	Rationale and study of IGF-1R in Ewing sarcoma <ul style="list-style-type: none">• SARC011 Phase 2 IGF-1R in Ewing’s in selected sarcoma subtypes• SARC013 Phase 3 Chemotherapy and R1507 or placebo in metastatic Ewing’s	Lee Helman Alberto Pappo Paul Meyers
10:30-10:50	Advancing care of GIST patients <ul style="list-style-type: none">• SARC 015 Phase 2 R1507 in wild-type GIST• SARC 009 Phase 2 Dasatinib in metastatic GIST• SARC 019 Phase 3 Imatinib PK testing in metastatic GIST	George Demetri Katie Janeway Jonathan Trent Suzanne George
10:50-11:10	Src Kinase Inhibition of Osteosarcoma <ul style="list-style-type: none">• SARC 012 Phase 2 Sarcatinib in recurrent osteosarcoma/SARC009 Dasatinib in the osteosarcoma cohort	Su Young Kim
11:10-11:30	Collaboration with EORTC <ul style="list-style-type: none">• EORTC 62091/SARC020 Phase 2b EORTC study of ET743 in metastatic STS	Bihn Bui
11:30-12:00	Closed Session: SARC Business Update (SARC Participants Only)	